European Court of Justice clarifies law on advertising of medicinal products
This article was originally published in SRA
The European Court of Justice has clarified the European Union’s legal position on the advertising of medicinal products, ruling that a third party could infringe European law despite acting independently of the manufacturer or seller.
You may also be interested in...
The European Directorate for the Quality of Medicines & HealthCare is proceeding carefully to find the right balance between serving the diverse requirements of various stakeholders that make use of its ‘certificates of suitability.’
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.